

Cloning and Tissue Expression of *Clusterin* in *Bufo gargarizans*

Guijin Jiang^{1,2}, Jinqiang Yuan^{1,2}, Ying Lin^{1,5}, Xin Gao^{1,3,4}, Xianyu Yang^{1,3,4*}

¹College of Animal Science and Technology, College of Veterinary Medicine, Zhejiang A&F University, Hangzhou 311300, China

²School of Forestry and Biotechnology, Zhejiang A&F University, Hangzhou 311300, China

³Key Laboratory of Applied Technology on Green-Eco-Healthy Animal Husbandry of Zhejiang Province, Hangzhou 311300, China

⁴Zhejiang Provincial Engineering Laboratory for Animal Health Inspection and Internet Technology, Hangzhou 311300, China

⁵Zhejiang Biosan Biochemical Technologies Co. Ltd., Hangzhou 310012, China

***Corresponding Author: Xianyu Yang,** College of Animal Science and Technology, College of Veterinary Medicine, Zhejiang A&F University, Hangzhou 311300, China

Abstract: Clusterin (CLU) has become an important target in cancer-therapy and new anti-tumor drug development. In current study, cloning of CLU open reading frame (ORF) from Chinese toad by polymerase chain reaction (PCR) and CLU tissue distribution by real-time fluorescent quantitative PCR (qPCR) were carried out. As the results, 1 332 bp ORF (GenBank accession number: KX640823) was cloned encoding a protein consisting of 443 amino acid residues with 98% homology with Japanese toad CLU, which indicates the successful cloning of Chinese toad CLU ORF. qPCR indicated higher CLU expression in testis, and lower in other organs relative to the expression level in skin, while no expression was detected from spleen.

Keywords: Bufo gargarizans; Clusterin; Tissue distribution

1. INTRODUCTION

Amphibian skin and skin secretions are rich in bioactive ingredients ^[1,2]. *Bufo gargarizans* (Chinese toad) is such an amphibian species providing "ChanSu" (toad skin secretions), "ChanYi" (toad cortex) and "ChanPi" (toad skin), all are the valuable materials of Traditional Chinese Medicine used in many clinical prescriptions ^[3-5]. Cinobufacini injection is water extract of dried toad skin of Chinese toad and its antitumor effect has been demonstrated ^[6]. The polypeptide mixture isolated from Cinobufacini injection showed the same antitumor activity as injection itself in vitro indicating polypeptides as the main antitumor ingredients ^[7]. Recent years, the authors screened skin cDNA plasmid library of Japanese toad (*B. japonicus formosus*), and some cDNAs with great potential for new-drug development have been cloned, such as *MCL1* ^[8], *SCP2* ^[9], *TAGLN2* ^[10], *PPDFP* ^[11] and *CLU* ^[12].

CLU, also known as SGP-2 (sulphated glycoproterin-2), TRPM-2 (testosterone repressed message-2) or APOJ (apolipoprotein J) ^[13], is divided into nuclear type (nCLU) and secretory type (sCLU) according to their locations in the cells ^[14]. sCLU is a highly glycosylated multifunctional protein, which is widely expressed in a variety of mammalian tissues and participates in many physiological processes, such as cell cycle regulation, DNA repair, and angiogenesis ^[15]. Recent studies have shown over-expression of *CLU* in several cancers, whose blocking enhances tumour cell sensitivity to chemotherapy and radiotherapy, therefore, *CLU* has become an important therapeutic target for cancer treatment ^[14,16].

Due to the lack of *CLU* data of Chinese toad, cloning of *CLU* open reading frame (ORF) by DNA polymerase chain reaction (PCR) and its tissue distribution by real-time fluorescent quantitative PCR (qPCR) were carried out in current study.

International Journal of Research Studies in Biosciences (IJRSB)

2. MATERIALS AND METHODS

2.1. Materials

Chinese toad was captured on the East lake Campus of Zhejiang A&F University, and ice anaesthetized before dissection. Their organs were removed and chopped into liquid nitrogen, which were kept at -80°C for RNA extraction later. The RNA Extraction Kit was purchased from Bocai Biotechnology Company (Shanghai, China); Real Master Mix (SYBR Green) for qPCR from Tiangen Biotechnology Limited Company (Beijing, China); PrimeScriptTM II 1st Strand cDNA Synthesis Kit and *Taq* PCR Kit from TaKaRa (Dalian, China). Primer synthesis, TA cloning of PCR products and DNA sequencing were done by GENEWIZ (Suzhou, China).

2.2. Methods

RNA extraction and the first strand cDNA preparation RNA extraction and cDNA preparation of each organ of Chinese toad were followed Manufactures' Instructions as reported previously^[9,11].

CLU ORF cloning for cloning of Chinese toad *CLU* ORF, primers (F1/R1) were designed based on the full length *CLU* cDNA of Japanese toad (GenBank accession number: JX035891) (Table 1). The reaction system of PCR was given in Table 2 and PCR was performed at 94°C for 40 secs, 54°C for 40 secs and 72°C for 90 secs, 30 cycles.

Sequence Analysis DNAstar/EditSeq was used to find ORF and deduce the amino acid sequence of encoded protein. Eleven CLU sequences of other animals were downloaded (http://blast.ncbi.nlm.nih. gov/Blast.cgi), which were aligned and the phylogenetic tree was constructed with DNAstar/ MegAlign.

Table 1. Primers used in current study

Primer	Sequence (5'-3')	Primer	Sequence(5'-3')
F1	GGACTCCAGAGCCGGA	R1	CAAAGCCCATTGTGTCC
F2	GGT GGTCATTCTGTTCAG	R2	GCCCTCCTTGTGCCTC
F3	TTGAGACCTTCAACACC	R3	CTTGATGTCACGCACAA

Table 2. PCR constitution

Components	Taq PCR	qPCR
$10 \times Taq$ buffer	2.0 μl	0.0 μl
10 mM dNTPs	0.8 µl	0.0 μl
<i>Taq</i> (5U/ μl)	0.2 μl	0.0 μl
2×qPCR Master Mix	0.0 µl	5.0 μl
Primer F (2 pmol/ µl)	1.0 μl	0.5 μl
Primer R (2 pmol/ µl)	1.0 µl	0.5 μl
First strand cDNA	1.0 μl	0.5 μl
H ₂ O	14.0 μl	3.5 μl

CLU Tissue distribution analysis Primers both for *CLU* qPCR (F2/R2) (designed based on Chinese toad *CLU* ORF) and for reference gene of β -actin (F3/R3)^[9,11] were given in Table 1. qPCR reaction system was given in Table 2, which was performed at 95°C for 3 secs, 52°C for 30 secs, 72°C for 20 secs, 40 cycles. For each organ, cDNA from 3 individuals were used and the expression level of *CLU* was relative to that of skin.

3. RESULTS

CLU cloning and homology analysis Sequencing analysis showed 1 332 bp *CLU* ORF of *B. gargarizans* (GenBank accession number: KX640823), which is the same as that of Japanese toad ^[12], while 23 bases are different between them (Fig. 1). Homology analysis at amino acid level indicated 98% between Chinese toad and Japanese toad, 65% with *Xenopus laevis* (NP_001080775.1) and *X. tropicalis* (AAH75303.1), and 42%~49% with *Homo sapiens* (NP_001822.3), *Pan troglodyte* (XP_001164647.1), *Gallus gallus* (NP_990231.1), *Numida meleagris* (AW21812.1), *Chelonia mydas* (XP_007071391.1), *Alligator sinensis* (XP_006033945.1), *Latimeria chalumnae* (P_006004784.1) and *Danio rerio* (AAQ56181.1) (Fig. 2). Phylogenetic tree showed two *Bufo* species get together, two *Xenopus* species gather together, while all these 4 amphibians converge in one large branch (Fig. 3), which is consistent with the traditional animal taxonomy. Further analysis indicated 5 amino acids are different between two *Bufo* species (asterisks in Fig. 2), the first two locate in signal peptide (dot-line

in Fig. 2), the 3rd in non-conserved area, the 4th in X position of the 3rd N-glycosylation area (Asn-X-Ser/Thr), and the last one in unimportant domain (Fig. 2). Other important characteristics of CLU are conserved completely between Chinese and Japanese toads including 5 disulfide bonds, 6 N-glycosylated structures and 2 coiled coil regions (Fig. 2).

Bufo gargarizans Bufo japonicus formosus	ATGAAGTCGTTTGCTCTCTACCTCCCCGGTGGTCATTCTGTCAGTCGCGCTGAGGCCTTGAGGCCCTGAGACCCTGAAACAGATCTCGGAGGAGGGGGGGG	111 111
Bufo gargarizans	GTCACCACCCAGTTTGAGAACGCCCTGAATGGAGTGACACAGATGAAGCTGCTGATGGACCAAGCTGCGCGGGAGCACCAGGAGATCCTGCGCTCTCGGAGGAGCACAAG	222
Bufo japonicus formosus	GTCACCACCCAGTTTGAGAACGCCCTGAATGGAGTGACACAGATGAAGCTGCTGATGGACCAAGCGGGGGGGG	222
Bufo gargarizans	AGGCA TA AGGAGGGGCGCCATGAAAGATGCGCTAGAATCGGAGCAGCAGCTGTGGGAGCATCTCAGGAGATCTGCAACGACACGGTGCTTGCGCTGTGGGAGGAGTGTAAACCC	333
Bufo japonicus formosus	AGGCA AGGAGGGGGCGCCATGAAAGATGCGCTAGAATCGGAGCAGCAGCTTGCGACGACGTCTGCAACGACACGGTGCTTGCGACGGAGGGGGGGG	333
Bufo gargarizans Bufo japonicus formosus	TGCTTAAAGCAAAGCTGTGTCCGGTTCTACTCCAAGACCTGCCGGGGCGGCTGGGGCGGGC	444 444
Bufo gargarizans	TTTATCAATGGAGAGAAGGTOGATGCTTTGAGCAAGCAGGACGAGCAGCAGCACATGOCCTGGAAGACCTGGAGAGAOCGGCTACAGCATTGTGGAGGACAGTGTGGATGAG	555
Bufo japonicus formosus	TTTATCAATGGAGAGAAGGTOGATGCTTTGAGCAAGCAGGACGAGCAGCAGCACCATGOCCTGGAAGACCTGGAGGAGGGCTACAGCATTGTGGAGGACAGTGTGGATGAG	555
Bufo gargarizans	CTCTTCCAGGAGAGCATGAAAGCCTTCGCCCACATGAAACCCTTTGTCACCAGTGCTTTCCAGGGTACGCCCAATTTCCCAGGGTGGAACCCGTTTCCTTTCGATAGACTC	666
Bufo japonicus formosus	CTCTTCCAGGAAAGCATGAAAGCCTTCGCCCACATGAAACCCTTTGTCACCAGTGCTTTCCAGGGTACGCCCCAATTTCCCAAGGTGGAACCCGTTTCCTTTCGATAGACTC	666
Bufo gargarizans	AACTTCCCCTTCCATCATCCCGCAGGGAGCGCTCCACTCTCTCGACCCATTTTTTCCAGGCAACTTCGAGTCTCTTTTGATGCTGCAAAGAAGATCATGGAAAGA	777
Bufo japonicus formosus	AACTTCCCCTTCCATCALCCATCCCGCAGGGAGCGCTCCACTCTTCTGACCCATTTTTTCCAGGCAACTTCGAGTCTCTTTTTGATGCTGCAAAGAAGATCATGGAAAGA	777
Bufo gargarizans	CACAACCAGCTGGCACGACAACCCACCCAGGGCCAAGGGAATTGAAAGATGATAAAGTGGTCTGCCAGGAGCTGAGGAGGAACTCTGCCGGGTGCCTGAAGATGAAGGAG	888
Bufo japonicus formosus	CACAACCAGCTGGCACGACAACCCACCCAGGGCCAAGGGAATTGAAAGAGTGATAAAGTGGTCTGCCAGGAGCTGAGGAGAACTCGGCGGGGCCCTGAAGATGAAGGAG	888
Bufo gargarizans	AAGTGTGAAAAGTGCAAGGAGATCCTAGCGATTGACTGGACCAACAGAAATCAAGTGCAAGAGAAATTAAAGGAGAAGTTTGAGGAATCCATTCGTGTGGCTGAGAAGTTC	999
Bufo japonicus formosus	AAGTGTGAAAAGTGCAAGGAGATCCTAGCGATTGACTG <mark>A</mark> ACCAACAGAAATCAAGTGCAAGAGAAATTAAAGGAGAAGTTTGAGGAATCCATTCGTGTGGCTGAGAAGTTC	999
Bufo gargarizans	ACCCGGCAGTATGAAGACTTACTGCAGAGGTTCCGGGAĞAAGATGCTAAATGCGACCAGTGTTCTAGAAGACTTAAGTCAGCAA	1110
Bufo japonicus formosus	ACCCGGCAGTATGAAGACTTACTGCAGAGGTTCCGGGAGAAAAGATGCTAAATGCGACCAGTGTTCTAGAAGACTTAAGTCAGCAA	1110
Bufo gargarizans	CTCACCCAGGGTGACAGGAATGGAATATTCCAAGTATCAACAGCATATTCCAGCAGTGGTGGGGGAACCATCTGAGACGACTGTAACAGTGAACCTTTTTGACTCTGAGCC	1221
Bufo japonicus formosus	CTCACCCAGGGTGACAGGAAGGGAATATTCCAAGTATCTAACAGCATATTCCAGCAGTGGTGGGGGAACCATCTGAGACGACTGTAACAGTGAACCTTTTTGACTCTGAGCC	1221
Bufo gargarizans Bufo japonicus formosus	TTCACCTTCACTGTACCGGGCAATATCAGTATTGAGGATCCAAAACT <mark>H</mark> GCAGAGCTCATAGCTGAGGAGGCTTTGAAGAGATTCAAGAAAGA	1332 1332

Fig1. Comparison of CLU ORF between B. gargarizans and B. japonicas formosus

Shade: Different nucleotide between two Bufo species. *: Missense. **: Synonymous



Fig2. Alignment of CLU amino acid sequence between B. gargarizans and other animals

Dot-line: Signal peptide. Line: coiled coil region. *: Different amino acid residue between two *Bufo* species. Double-line: Cysteine residue. Rectangle: Location of N-glycosylation (Asn-X-Ser/Thr, X indicates any amino acid residue).

CLU tissue distribution to clarify the tissue distribution of *CLU* in Chinese toad, qPCR was performed (Fig. 4), which indicated higher expression in testicle, lower in heart, liver, lung, kidney, intestine and stomach relative to the expression level in skin, but no expression was detected from spleen.

4. DISCUSSIONS

In current study, *CLU* ORF of *B. gargarizans* (Fig. 1) was successfully cloned, whose encoding protein showed 98% homology with that of Japanese toad (Fig. 2 and 3) ^[12]. All-important characteristics of CLU are completely conserved between Chinese toad and Japanese toad including 5

disulfide bonds, 6 N-glycosylated structures and 2 coiled coil regions suggesting the same function of CLU of both *Bufo* species. qPCR analysis discovered higher expression in testis (Fig. 4).



Fig3. Phylogenetic tree based on CLU amino acid sequences of B. gargarizans and 11 other animals



Fig4. qPCR analysis of CLU expression in different organs of B. gargarizans

Abscissa: Organs of *B. gargarizans*. Ordinate: *CLU* expression level relative to skin. Error bars: Standard deviation from the data of 3 individuals.

Concerning the mechanism of *CLU* expression, although it is not so clear currently, but influenced by cytokines, growth factors as well as stress ones such as oxidative stress, heat shock, chemotherapy and radiotherapy ^[14,17]. According to previous reports, the tolerance to chemotherapy and radiotherapy is closely related with *CLU* expression in several cancers, and *CLU* up-regulation has been confirmed in many cancers including prostate, kidney, bladder, breast, head and neck, colon, cervical, pancreatic, lung, melanoma lymphoma ^[16,18]. Therefore, *CLU* has been considered as a biomarker for tumour malignancy, and it is believed that improvement of tumour cell sensitivity to chemotherapy and radiotherapy is promising way to control cancer by reducing *CLU* expression ^[14,19-21].

Cinobufacini as an anticancer drug, its polypeptide mixture has been demonstrated to have the same antitumor activity as the injection itself, whose molecular weight is 3~5 kDa^[7]. In fact, Cinobufacini also works as oral liquid, tablet and capsule. These studies indicated toad skin protein might function in short peptides instead of intact protein. For example, Buforin I and II are antimicrobial polypeptides consisting of 1-39 and 16-36 amino acid residues of *B. gargarizans* H2A, respectively^[22]. Abhisin is 1-40 amino acid residues of *Haliotis discus* H2A having antibacterial activity as well as anti-endotoxin and anti-tumor activity^[23]. NuBCP-9 (the 489-497 amino acid residues of Nur77) had good antitumor activity^[24,25]. Although there is no direct evidence shown CLU or CLU-derived peptide included in toad skin or Cinobufotini, *CLU* ORF does have been cloned from skin first-strand cDNA of *B. gargarizans* here and *CLU* full-length cDNA from Japanese toad skin cDNA library^[12]. Therefore, CLU is probably one of the anti-tumor peptides included in toad skin, which might function as an antagonist of native *CLU*. The expression of *CLU* in most organs of Chinese toad (Fig. 4) further indicates the promise for the importance of *Bufo* skin origin materials in anti-tumor drug development.

ACKNOWLEDGEMENT

This work was partially supported by the grant from National Natural Science Foundation of China (No. 31772409, 31372149).

REFERENCES

- [1] Clarke BT. The natural history of amphibian skin secretions, their normal functioning and potential medical applications. Biol Rev Camb Philos Soc 1997, 72(03): 365-379.
- [2] Gomes A, Bhattacharjee P, Mishra R, Biswas AK, Dasgupta SC, Giri B. Anticancer potential of animal venoms and toxins. Indian J Exp Biol 2010, 48(2): 93-103.
- [3] Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M, Tang W. Antitumor activity of extracts and compounds from the skin of the toad *Bufo bufo gargarizans* cantor. Int Immunopharmacol 2011, 11(3): 342-349.
- [4] Li C, Hashimi SM, Cao S, Mellick AS, Duan W, Good D. The mechanisms of Chansu in inducing efficient apoptosis in colon cancer cells. Evid Based Complement Alternat Med 2013, 2013: 1-11.
- [5] Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol 2008, 14(33): 5210-5216.
- [6] Qi F, Li A, Inagaki Y, Xu H, Wang D, Cui X, Zhang L, Kokudo N, Du G, Tang W. Induction of apoptosis by cinobufacini preparation through mitochondria- and Fas-mediated caspase-dependent pathways in human hepatocellular carcinoma cells. Food & Chemical Toxicology 2012, 50(2): 295-302.
- [7] Wu X, Gao B, Yang J, Bian BL, Wang HJ. In vitro anti-proliferation effect of peptides from cinobufacini injection. Acta Pharmaceutica Sinica 2012, 47(6): 822-826. (in Chinese)
- [8] Hu QL, Zhang SF, Yang XY, Yu MH, and Zhuge H. *Bufo gargarizans* mcl-1 cloning and its prokaryotic recombinant protein expression. Acta Pharmaceutica Sinica 2013, 48(10): 1624-1628. (in Chinese)
- [9] Ji YC, Zhuge H, Zhang SS, Zhang SF, and Yang XY. Cloning the sterol carrier protein 2 genes of Japanese toad (*Bufo japonicus formosus*) and Chinese toad (*Bufo gargarizans*) and its tissue expression analysis. Zoological Research 2014, 35(5): 398-403.
- [10] Zhuge H, Yuan JQ, Zhang SF, Yang XY. Cloning and bioinformatic analysis of TAGLN2 cDNA of Bufo japonicus formosus. Acta Pharmaceutica Sinica 2013, 48(2): 250-254. (in Chinese)
- [11] Yue J, Jiang G, Yang X, Wang H, Zhao L. PPDPF cDNA cloning from two *Bufo* species and tissue expression in *B. gargarizans*. IJRSB 2018, 6(4): 35-40.
- [12] Yuan JQ, Xu Y, Yang XY, Zhuge H, Zhang SF. Cloning and sequence analysis of clusterin cDNA of *Bufo japonicus formosus*.Biotechnol Bull 2013, (1): 156-161. (in Chinese)
- [13] Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A, Bettuzzi S. Clusterin (SGP-2, ApoJ) expression in down-regulated in low- and high-grade human prostate cancer. Int J Cancer 2004, 108(1): 23-30.
- [14] García-Aranda M, Téllez T, Muñoz M, Redondo M. Clusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancer. Anticancer Drugs 2017, 28(7): 702-716.
- [15] Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002, 34(5):427-431.
- [16] Tellez T, Garcia-Aranda M, Redondo M. The role of clusterin in carcinogenesis and its potential utility as therapeutic target. Curr Med Chem 2016, 23(38): 4297-4308.
- [17] Koltai T. Clusterin: a key player in cancer chemoresistance and its inhibition. Onco Targets Ther 2014, 7:447-56.
- [18] Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res 2009,105:77-92.
- [19] Xiu P, Xu Z, Liu F, Li Z, Li T, Zou F, Sun X, Li J. Down regulating sCLU enhances the sensitivity of hepatocellular carcinoma Cells to gemcitabine by activating the intrinsic apoptosis pathway. Digestive Diseases & Sciences 2014, 59(8): 1798-1809.
- [20] Ma G, Cai H, Gao L, Wang M, Wang H. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo. World J Surg Oncol 2015, 13:80.
- [21] Huang MB, Gonzalez RR, Lillard J, Bond VC. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cacer cells. Oncotarget 2017, 87(7): 11302-11315.
- [22] Cho JH, Sung BH, Kim SH. Buforins: Histone H2A-derived antimicrobial peptides from toad stomach. Biochimica et Biophysica Acta 2009, 1788 (8): 1564-1569.

- [23] De Zoysa M, Nikapitiya C, Whang I, Lee JS, Lee J. Abhisin: a potential antimicrobial peptide derived from histone H2A of disk abalone (*Haliotis discus discus*). Fish Shellfish Immunol 2009, 27(5):639-46.
- [24] Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116(4):527-540
- [25] Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, Tian X, Town J, Cao X, Lin F, Zhai D, Kitada S, Luciano F, O'Donnell E, Cao Y, He F, Lin J, Reed JC, Satterthwait AC, Zhang XK. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008, 14(4): 285-98.

Citation: Xianyu Yang, et.al, "Cloning and Tissue Expression of Clusterin in Bufo gargarizans" International Journal of Research Studies in Biosciences (IJRSB), 8(3), pp 1-6. DOI: http://dx.doi.org/10.20431/2349-0365.0803001

Copyright: © 2020 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.